Clinical trial • Phase I • Other

Vafidemstat for Healthy volunteers

Phase I trial of Vafidemstat for Healthy volunteers. open-label, none/not specified-controlled. 8 participants.

Overview

Trial Therapeutic Area
Other
Trial Disease
Healthy volunteers
Trial Stage
Phase I
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
24-03-2026
First CTIS Authorization Date
30-04-2026

Trial design

open-label, none/not specified-controlled Phase I trial across 1 site in Netherlands.

Open Label
Yes
Comparator
None/Not specified
Target Sample Size
8

Eligibility

Recruits 8 No vulnerable populations selected; study population: healthy male participants; consent details not provided..

Vulnerable Population
No vulnerable populations selected; study population: healthy male participants; consent details not provided.

Recruitment

Planned Sample Size
8
Recruitment Window Months
1
Consent Approach
Informed consent process not described. Participants are healthy male adults; consent/assent documents and languages not provided.

Geography

Total Number Of Sites
1
Total Number Of Participants
8

Netherlands

Earliest CTIS Part Ii Submission Date
24-04-2026
Latest Decision Or Authorization Date
30-04-2026
Processing Time Days
6
Number Of Sites
1
Number Of Participants
8

Sites

Site Name
Pharmaceutical Research Associates Group B.V.
Department Name
Program Management
Contact Person Name
Renger Tiessen
Contact Person Email
renger.tiessen@iconplc.com

Sponsor

Primary sponsor

Full Name
Oryzon Genomics S.A.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Contract research organisations

Name
Pharmaceutical Research Associates Group B.V.
Responsibilities
Program Management; site contact (person: Renger Tiessen, email: renger.tiessen@iconplc.com)

Investigational products

Investigational Product Name
[14C]-VAFIDEMSTAT
Active Substance
Vafidemstat
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral

Related trials

Other published trials that may interest you.